# US 2026/0092058 A1 · Small Molecule Degraders and Fluorescent Probes of PXR

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092058 A1
- Document ID: US20260092058A1
- Status: Published application
- Kind: A1
- Application number: 18/902,844
- Filed: 2024-09-30
- Published: 2026-04-02
- Earliest claimed: 2024-09-30
- Applicants: St. Jude Children's Research Hospital, Inc.
- Inventors: Taosheng Chen; Andrew Huber; Young-Hwan Jung; Yongtao Li; Wenwei Lin
- Web page: https://patentgrep.com/patent/US20260092058A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07F 5/022: {without C-boron linkages}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure in one aspect, relates to compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention further relates to the use of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse drug reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, or an anticonvulsant agent. The invention, in one aspect, further relates to compounds, compositions, and methods for identifying PXR ligands. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of degrading a target protein in a cell, the method comprising contacting the cell with an effective amount of a compound having a structure represented by a formula:
wherein L is a linker;
wherein R1 is a residue of a pregnane X receptor (PXR) ligand; and
wherein R2 is a residue of a Cereblon (CRBN) ligand or a residue of a von Hippel-Lindau protein (pVHL) ligand,
or a pharmaceutically acceptable salt thereof.

### Claim 13

A method of degrading a target protein in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:
wherein L is a linker;
wherein R1 is a residue of a pregnane X receptor (PXR) ligand; and
wherein R2 is a residue of a Cereblon (CRBN) ligand or a residue of a von Hippel-Lindau protein (pVHL) ligand,
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject has been diagnosed as having a condition that results from activation of the target protein, and wherein the condition is due to a PXR-mediated metabolism event.

### Claim 15

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:
wherein L is a linker;
wherein R1 is a residue of a pregnane X receptor (PXR) ligand; and
wherein R2 is a residue of a Cereblon (CRBN) ligand or a residue of a von Hippel-Lindau protein (pVHL) ligand,
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the disease or disorder is cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is selected from a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma).

### Claim at position 8

18-20. (canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein R2 is the residue of the pVHL ligand.

### Claim 22 (depends on 21)

The method of claim 21, wherein the residue of the pVHL ligand has a structure selected from:

### Claim 23 (depends on 21)

The method of claim 21, wherein the residue of the pVHL ligand has a structure represented by a formula:
wherein Q1 is selected from *—C(O)—**, *—OC(O)—**, *—C(R20a)(R20b)C(O)—**, *—OC(R20a)(R20b)C(O)—**, *—C(R20a)(R20b)C(O)C(cyclopropyl)C(O)—**, *—C(R20a)(R20b)C(O)N(R21a)CH2CH(R21b)C(O)—**, *—C(C3-C4 cycloalkyl)C(O)—**, *—NH(CH2CH2O)qCH2C(O)—**, *—NHCH2C(cyclopropyl)C(O)—**, and *—CH2C(O)N(R22)CH(R23)C(O)—**, wherein * denotes a bond connected to -L- and ** denotes a bond connected to —N(R3)—;
wherein q is selected from 1, 2, 3, 4, 5, and 6;
wherein each of R20a and R20b is independently selected from hydrogen and C1-C4 alkyl;
or wherein each of R20a and R20b are covalently bound, and, together comprise a C3-C4 cycloalkyl or a C2-C3 heterocycloalkyl;
or wherein R20 is covalently bound to R3, and, together with the intermediate atoms, comprises a 5-membered heterocycle;
wherein each of R21a and R21b are covalently bound, and, together with the intermediate atoms, comprise a 4-membered heterocycle;
wherein R22 is hydrogen; and
wherein R23 is selected from C1-C4 alkyl, —CH2C6H5, and —C6H5;
or wherein each of R22 and R23 are covalently bound, and, together with the intermediate atoms, comprise an 10-membered heterocycloalkyl;
wherein R3 is selected from hydrogen and C1-C4 alkyl; and
wherein R4 is selected from C1-C4 alkyl, C1-C4 hydroxyalkyl, and C6H5;
or wherein each of R3 and R4 are covalently bound, and, together with the intermediate atoms, comprise a 5- or 6-membered heterocycle having 0 or 1 —OH group;
or wherein each of R3 and R20a, when present, are covalently bound, and, together with the intermediate atoms, comprise a 5-membered heterocycle;
wherein R5 is selected from hydrogen and methyl; and
wherein R6 is selected from hydrogen, —OH, and C1-C4 alkyl halide.

### Claim 24 (depends on 23)

The method of claim 23, wherein Q1 is *—C(R10a)(R10b)C(O)—**.

### Claim 25 (depends on 15)

The method of claim 15, wherein L is selected from *—(C3-C24 alkylene)-**, *—(C3-C24 alkoxy)-**, *—(CH2CH2O)n—**, *—(CH2CH2O)n(C1-C4 alkyl)-**, and a structure selected from:
wherein * denotes a bond connected to R1 and ** denotes a bond connected to R2, and wherein n is selected from 2, 3, 4, 5, 6, 7, and 8.

### Claim 26 (depends on 25)

The method of claim 25, wherein L is *—(CH2CH2O)n—**.

### Claim 27 (depends on 15)

The method of claim 15, wherein the residue of the PXR ligand has a structure represented by a formula:
wherein A is selected from *—SO2—**, *—NR24C(O)—**, *—N(R24)C(O)NR25—***—C(O)NR24—**, *—SO2NR24—**, and *—NR24SO2—**, wherein * denotes a bond connected to the triazole and ** denotes a bond connected to the phenyl;
wherein each of R24 and R25 is independently selected from hydrogen and C1-C4 alkyl;
wherein Q2 is selected from *—O—**, *—O(C1-C8 alkylene)-**, *—OCH2C(O)NH—**, and *—C(O)NH—**, wherein * denotes a bond connected to the phenyl and ** denotes a bond connected to -L-;
wherein Z is selected from N and CH;
wherein R7 is selected from hydrogen and C1-C4 alkyl;
wherein R8a is selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and C1-C4 haloalkoxy;
wherein R9 is C1-C4 alkyl; and
wherein each of R10a, R10b, R10c, R10d, and R10e is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C8 alkyl, C2-C8 alkenyl, C1-C8 haloalkyl, C1-C8 cyanoalkyl, C1-C8 hydroxyalkyl, C1-C8 haloalkoxy, C1-C8 alkoxy, C1-C8 alkylamino, (C1-C8)(C1-C8) dialkylamino, C1-C8 alkylamino, and —C02(C1-C4 alkyl).

### Claim 28 (depends on 27)

The method of claim 27, wherein A is selected from *—C(O)NR24—** and *—SO2NR24—**.

### Claim 29 (depends on 27)

The method of claim 27, wherein the compound has a structure represented by a formula:
wherein n is selected from 2, 3, 4, 5, 6, 7, and 8,
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 15)

The method of claim 15, wherein the compound has a structure represented by a formula:
wherein A is selected from *—SO2—**, *—NR24C(O)—**, *—N(R24)C(O)NR25—***—C(O)NR24—**, *—SO2NR24—**, and *—NR24SO2—**, wherein * denotes a bond connected to the triazole and ** denotes a bond connected to the phenyl;
wherein each of R24 and R25 is independently selected from hydrogen and C1-C4 alkyl;
wherein Q1 is selected from *—C(O)—**, *—OC(O)—**, *—C(R20a)(R20b)C(O)—**, *—OC(R20a)(R20b)C(O)—**, *—C(R20a)(R20b)C(O)C(cyclopropyl)C(O)—**, *—C(R20a)(R20b)C(O)N(R21a)CH2CH(R21b)C(O)—**, *—C(C3-C4 cycloalkyl)C(O)—**, *—NH(CH2CH2O)qCH2C(O)—**, *—NHCH2C(cyclopropyl)C(O)—**, and *—CH2C(O)N(R22)CH(R23)C(O)—**, wherein * denotes a bond connected to -L- and ** denotes a bond connected to —N(R3)—;
wherein q is selected from 1, 2, 3, 4, 5, and 6;
wherein each of R20a and R20b is independently selected from hydrogen and C1-C4 alkyl;
or wherein each of R20a and R20b are covalently bound, and, together comprise a C3-C4 cycloalkyl or a C2-C3 heterocycloalkyl;
or wherein R20 is covalently bound to R3, and, together with the intermediate atoms, comprises a 5-membered heterocycle;
wherein each of R21a and R21b are covalently bound, and, together with the intermediate atoms, comprise a 4-membered heterocycle;
wherein R22 is hydrogen; and
wherein R23 is selected from C1-C4 alkyl, —CH2C6H5, and —C6H5;
or wherein each of R22 and R23 are covalently bound, and, together with the intermediate atoms, comprise an 10-membered heterocycloalkyl;
wherein Q2 is selected from *—O—**, *—O(C1-C8 alkylene)-**, *—OCH2C(O)NH—**, and *—C(O)NH—**, wherein * denotes a bond connected to the phenyl and ** denotes a bond connected to -L-;
wherein Z is selected from N and CH;
wherein R3 is hydrogen or C1-C4 alkyl; and
wherein R4 is a C1-C4 alkyl, C1-C4 hydroxyalkyl, or C6H5;
or wherein each of R3 and R4 are covalently bound, and, together with the intermediate atoms, comprise a 5- or 6-membered heterocycle having 0 or 1 —OH group;
or wherein each of R3 and R10, when present, are covalently bound, and, together with the intermediate atoms, comprise a 5-membered heterocycle;
wherein R5 is hydrogen or methyl;
wherein R6 is hydrogen, —OH, or C1-C4 alkyl halide;
wherein R7 is selected from hydrogen and C1-C4 alkyl;
wherein R8a is selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and C1-C4 haloalkoxy;
wherein R9 is C1-C4 alkyl; and
wherein each of R10a, R10b, R10c, R10d, and R10e is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C8 alkyl, C2-C8 alkenyl, C1-C8 haloalkyl, C1-C8 cyanoalkyl, C1-C8 hydroxyalkyl, C1-C8 haloalkoxy, C1-C8 alkoxy, C1-C8 alkylamino, (C1-C8)(C1-C8) dialkylamino, C1-C8 alkylamino, and —CO2(C1-C4 alkyl), or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein the compound has a structure represented by a formula:
wherein n is selected from 2, 3, 4, 5, 6, 7, and 8,
or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 15)

The method of claim 15, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 15)

The method of claim 15, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
